Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
6.764 JPY | +1,87 % | -0,22 % | -4,08 % |
15.05. | BioArctic und Eisai starten rollenden US-FDA-Antrag für die Erhaltungsdosis von Leqembi | MT |
15.05. | Transcript : Eisai Co., Ltd., 2024 Earnings Call, May 15, 2024 |
Kurzporträt
- pharmazeutische Produkte (87,7%): verschreibungspflichtige Medikamente, Gesundheitsprodukte, etc;
- Sonstige (12,3%): Lebensmittelzusatzstoffe, chemische Produkte, usw.
Der Nettoumsatz verteilt sich geographisch wie folgt: Japan (46,2%), Europa (19,5%), Amerika (15,5%), China (10,3%) und Sonstige (8,4%).
Mitarbeiterzahl: 11 076
Umsatz nach Geschäftsbereich
JPY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Pharmaceutical
91,9
%
| 626 281 | 82,8 % | 684 434 | 91,9 % | +9,29 % |
Other
8,1
%
| 129 945 | 17,2 % | 59 969 | 8,1 % | -53,85 % |
Umsatz je Region
JPY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Japan
33,6
%
| 243 385 | 32,2 % | 250 327 | 33,6 % | +2,85 % |
Americas
32,1
%
| 226 719 | 30,0 % | 239 293 | 32,1 % | +5,55 % |
China
14,6
%
| 106 592 | 14,1 % | 108 562 | 14,6 % | +1,85 % |
Europe
11,6
%
| 126 745 | 16,8 % | 86 026 | 11,6 % | -32,13 % |
Other
8,1
%
| 52 784 | 7,0 % | 60 195 | 8,1 % | +14,04 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01.10.75 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yasushi Okada
COO | Chief Operating Officer | 65 | 01.04.81 |
Yosuke Akita
CMP | Compliance Officer | 59 | 01.04.89 |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 01.04.88 |
Hideki Hayashi
BRD | Director/Board Member | 66 | 01.04.81 |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 01.04.82 |
Masatomi Akana
IRC | Investor Relations Contact | 57 | 01.04.90 |
Sayoko Sasaki
IRO | Public Communications Contact | 55 | 01.04.91 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01.10.75 |
Fumihiko Ike
BRD | Director/Board Member | 72 | 01.06.21 |
Hideki Hayashi
BRD | Director/Board Member | 66 | 01.04.81 |
Ryota Miura
BRD | Director/Board Member | 50 | 01.06.21 |
Yuko Yasuda
BRD | Director/Board Member | 62 | - |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 01.04.88 |
Hideyo Uchiyama
BRD | Director/Board Member | 71 | 01.06.18 |
Yumiko Miwa
BRD | Director/Board Member | 58 | 01.06.20 |
Director/Board Member | 59 | 17.06.22 | |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 01.04.82 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 296 566 949 | 278 292 124 ( 93,84 %) | 9 531 401 ( 3,214 %) | 93,84 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
EISAI CO., LTD. 3,21% | 9 531 401 | 3,21% | 393 818 045 $ |
MATSUKIYOCOCOKARA & CO. 1,97% | 8 445 000 | 1,97% | 120 585 395 $ |
474 000 | 0,96% | 10 918 884 $ | |
COGSTATE LIMITED 6,85% | 11 738 243 | 6,85% | 10 709 269 $ |
ROIVANT SCIENCES LTD. 0,11% | 874 957 | 0,11% | 9 519 532 $ |
VITAL KSK HOLDINGS, INC. 1,24% | 642 154 | 1,24% | 5 031 463 $ |
349 000 | 0,43% | 3 104 882 $ | |
546 000 | 2,24% | 2 973 483 $ | |
134 748 | 0,06% | 2 115 003 $ | |
56 608 | 0,14% | 177 704 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Eisai Ltd. (United Kingdom) is a pharmaceutical company based in Hatfield, UK. Part of Eisai Co., Ltd., Eisai Ltd. prioritizes patients and their families by continually improving the benefits that healthcare can provide. The British company was founded in 1988 and Gary Bryan Hendler has been the CEO of the company since 2008. |
Pharmaceuticals: Major
|
Eisai Manufacturing Ltd.
Eisai Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Manufacturing Ltd. is a pharmaceutical company based in Hatfield, UK. The British company's focus is on developing new medicines for neglected tropical diseases and malaria, improving access to medicines for non-communicable diseases, and promoting sustainability. Eisai Manufacturing is committed to funding the 3rd phase of health innovative technology fund activities. The company's official corporate website provides information on their initiatives and HHC concept. |
Pharmaceuticals: Major
|
Eisai Pharmaceuticals India Pvt Ltd.
Eisai Pharmaceuticals India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Pharmaceuticals India Pvt Ltd. is an Indian company that manufactures and exports drug substances. The company is based in Visakhapatnam, India. The company was founded in 2007. The CEO is Sanjit Singh Lamba. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-4,08 % | 12,12 Mrd. | |
+38,69 % | 728 Mrd. | |
+33,66 % | 603 Mrd. | |
-4,49 % | 360 Mrd. | |
+20,24 % | 332 Mrd. | |
+2,12 % | 279 Mrd. | |
+15,81 % | 244 Mrd. | |
+7,68 % | 207 Mrd. | |
-5,60 % | 205 Mrd. | |
-0,35 % | 163 Mrd. |
- Börse
- Aktien
- 855526 Aktie
- Unternehmen Eisai Co., Ltd.